{"filing":{"accession_number":"0001193125-26-390951","cik":"0001863127","ticker":"TYRA","company_name":"Tyra Biosciences, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"d102025d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/d102025d8k.htm"},"events":[{"id":33405,"run_id":30713,"accession_number":"0001193125-26-390951","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Tyra Biosciences entered into an underwriting agreement on September 14, 2026 to issue 9,079,000 shares of common stock at $22.03 per share and 9,078,529 pre-funded warrants, generating approximately $400 million in gross proceeds. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is a material capital-raising event typical of clinical-stage biotech companies. The filing explicitly references the shelf registration statement (Form S-3) and prospectus supplement, confirming this is a registered offering rather than a private placement, but the economic substance—issuance of equity to raise capital—remains a dilutive issuance material to investors.","company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36852,"accession_number":"0001193125-26-390951","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Tyra Biosciences entered into an underwriting agreement on September 14, 2026 to issue 9,079,000 shares of common stock at $22.03 per share and 9,078,529 pre-funded warrants, generating approximately $400 million in gross proceeds. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is a material capital-raising event typical of clinical-stage biotech companies. The filing explicitly references the shelf registration statement (Form S-3) and prospectus supplement, confirming this is a registered offering rather than a private placement, but the economic substance—issuance of equity to raise capital—remains a dilutive issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:05:49.417856+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36852,"accession_number":"0001193125-26-390951","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Tyra Biosciences entered into an underwriting agreement on September 14, 2026 to issue 9,079,000 shares of common stock at $22.03 per share and 9,078,529 pre-funded warrants, generating approximately $400 million in gross proceeds. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is a material capital-raising event typical of clinical-stage biotech companies. The filing explicitly references the shelf registration statement (Form S-3) and prospectus supplement, confirming this is a registered offering rather than a private placement, but the economic substance—issuance of equity to raise capital—remains a dilutive issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:05:49.417856+00:00","company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","filing_date":"2026-09-14"}]}